REVIEW Vildagliptin is a new oral anti-hyperglycemic agent (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. It is currently in clinical trials in the U.S. and has been shown to reduce hyperglycemia in type 2 diabetes mellitus. Vildagliptin appears to have multiple functional benefits beyond simple blood-glucose control. One of these is a potential protective effect on pancreatic beta cells, which deteriorate in diabetes.
REFERENCES
[1]
Henness, Sheridan; Keam, Susan J. Vildagliptin. Drugs. (2006) 66(15): 1989-2001.
[2]
Ahren, Bo. Vildagliptin: novel pharmacological approach to treat type 2 diabetes. Therapy. (2008) 5(1): 79-90.
[3]
He, Yan-Ling. Clinical pharmacokinetics and pharmacodynamics of vildagliptin. Clinical Pharmacokinetics. (2012) 51(3): 147-162.
[4]
Villhauer, Edwin Bernard Preparation of N-glycyl-2-cyanopyrrolidines as DPP IV inhibitors PCT Int. Appl. (2000), WO 2000034241 A1 20000615
All products are stocked and shipped from San Francisco Bay Area, California, USA.
⚠️
All products are for research and development use only, not for any other uses, and must be handled by technically-qualified persons.
These products are explicitly not intended to be used in foods and/or cosmetics and/or drugs (human and veterinary) and/or consumer products and/or biocides and/or pesticides of any kind unless explicitly stated otherwise.
Products are not sold to individuals. We do not ship to residential addresses. Consumer orders will be cancelled without notice.
New customers undergo an internal onboarding process. As part of this process, new customers may be asked for more information. Additional restrictions may apply.
Add to Favorites 
Delete from Favorites 
